Efficacy study of intensive cis‐platin therapy in advanced non‐small cell bronchogenic carcinoma

Steven E. Vogl, Marc Berenzweig, Fernando J. Camacho, Edward Greenwald, Barry H. Kaplan

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Thirty patients with advanced non‐small cell bronchogenic carcinoma were treated with cis‐platin, 75 mg/M2 weekly for three weeks, then every three weeks. Eighteen were ambulatory, 22 had distant metastases, 14 had prior irradiation, and none had prior chemotherapy. Ten patients (33%) had objective remissions lasting a median of three months. Responders lived a median of five months, compared to three months for nonresponders. Transient mild azotemia was noted in twelve patients. Cis‐platin has definite but modest activity in non‐small cell bronchogenic carcinoma.

Original languageEnglish (US)
Pages (from-to)24-26
Number of pages3
JournalCancer
Volume50
Issue number1
DOIs
StatePublished - Jan 1 1982

Fingerprint

Bronchogenic Carcinoma
Cisplatin
Azotemia
Therapeutics
Neoplasm Metastasis
Drug Therapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Efficacy study of intensive cis‐platin therapy in advanced non‐small cell bronchogenic carcinoma. / Vogl, Steven E.; Berenzweig, Marc; Camacho, Fernando J.; Greenwald, Edward; Kaplan, Barry H.

In: Cancer, Vol. 50, No. 1, 01.01.1982, p. 24-26.

Research output: Contribution to journalArticle

Vogl, Steven E. ; Berenzweig, Marc ; Camacho, Fernando J. ; Greenwald, Edward ; Kaplan, Barry H. / Efficacy study of intensive cis‐platin therapy in advanced non‐small cell bronchogenic carcinoma. In: Cancer. 1982 ; Vol. 50, No. 1. pp. 24-26.
@article{9cfd4e83f4bb409da375a378a977cdf3,
title = "Efficacy study of intensive cis‐platin therapy in advanced non‐small cell bronchogenic carcinoma",
abstract = "Thirty patients with advanced non‐small cell bronchogenic carcinoma were treated with cis‐platin, 75 mg/M2 weekly for three weeks, then every three weeks. Eighteen were ambulatory, 22 had distant metastases, 14 had prior irradiation, and none had prior chemotherapy. Ten patients (33{\%}) had objective remissions lasting a median of three months. Responders lived a median of five months, compared to three months for nonresponders. Transient mild azotemia was noted in twelve patients. Cis‐platin has definite but modest activity in non‐small cell bronchogenic carcinoma.",
author = "Vogl, {Steven E.} and Marc Berenzweig and Camacho, {Fernando J.} and Edward Greenwald and Kaplan, {Barry H.}",
year = "1982",
month = "1",
day = "1",
doi = "10.1002/1097-0142(19820701)50:1<24::AID-CNCR2820500106>3.0.CO;2-R",
language = "English (US)",
volume = "50",
pages = "24--26",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "1",

}

TY - JOUR

T1 - Efficacy study of intensive cis‐platin therapy in advanced non‐small cell bronchogenic carcinoma

AU - Vogl, Steven E.

AU - Berenzweig, Marc

AU - Camacho, Fernando J.

AU - Greenwald, Edward

AU - Kaplan, Barry H.

PY - 1982/1/1

Y1 - 1982/1/1

N2 - Thirty patients with advanced non‐small cell bronchogenic carcinoma were treated with cis‐platin, 75 mg/M2 weekly for three weeks, then every three weeks. Eighteen were ambulatory, 22 had distant metastases, 14 had prior irradiation, and none had prior chemotherapy. Ten patients (33%) had objective remissions lasting a median of three months. Responders lived a median of five months, compared to three months for nonresponders. Transient mild azotemia was noted in twelve patients. Cis‐platin has definite but modest activity in non‐small cell bronchogenic carcinoma.

AB - Thirty patients with advanced non‐small cell bronchogenic carcinoma were treated with cis‐platin, 75 mg/M2 weekly for three weeks, then every three weeks. Eighteen were ambulatory, 22 had distant metastases, 14 had prior irradiation, and none had prior chemotherapy. Ten patients (33%) had objective remissions lasting a median of three months. Responders lived a median of five months, compared to three months for nonresponders. Transient mild azotemia was noted in twelve patients. Cis‐platin has definite but modest activity in non‐small cell bronchogenic carcinoma.

UR - http://www.scopus.com/inward/record.url?scp=0019947425&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019947425&partnerID=8YFLogxK

U2 - 10.1002/1097-0142(19820701)50:1<24::AID-CNCR2820500106>3.0.CO;2-R

DO - 10.1002/1097-0142(19820701)50:1<24::AID-CNCR2820500106>3.0.CO;2-R

M3 - Article

C2 - 7044518

AN - SCOPUS:0019947425

VL - 50

SP - 24

EP - 26

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 1

ER -